XSTOXVIVO
Market cap1.35bUSD
Dec 23, Last price
473.00SEK
1D
1.39%
1Q
-5.31%
Jan 2017
437.50%
IPO
2,207.32%
Name
Xvivo Perfusion AB
Chart & Performance
Profile
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 597,542 43.88% | 415,292 60.73% | 258,386 43.66% | |||||||
Cost of revenue | 597,578 | 411,056 | 277,521 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (36) | 4,236 | (19,135) | |||||||
NOPBT Margin | 1.02% | |||||||||
Operating Taxes | 2,701 | 3,887 | (1,487) | |||||||
Tax Rate | 91.76% | |||||||||
NOPAT | (2,737) | 349 | (17,648) | |||||||
Net income | 91,820 398.29% | 18,427 126.04% | 8,152 -118.64% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 429,250 | 447 | 245,353 | |||||||
BB yield | -4.35% | -0.01% | -3.04% | |||||||
Debt | ||||||||||
Debt current | 10,268 | 5,550 | 4,199 | |||||||
Long-term debt | 52,606 | 14,460 | 7,243 | |||||||
Deferred revenue | 1,499 | |||||||||
Other long-term liabilities | 65,616 | 137,831 | 124,522 | |||||||
Net debt | (483,796) | (226,946) | (388,413) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 46,287 | 27,856 | (12,059) | |||||||
CAPEX | (43,015) | (130,946) | (94,074) | |||||||
Cash from investing activities | (161,619) | (197,624) | (187,703) | |||||||
Cash from financing activities | 418,547 | (6,842) | 234,611 | |||||||
FCF | (129,061) | (64,034) | (30,455) | |||||||
Balance | ||||||||||
Cash | 546,088 | 246,545 | 398,696 | |||||||
Long term investments | 582 | 411 | 1,159 | |||||||
Excess cash | 516,793 | 226,191 | 386,936 | |||||||
Stockholders' equity | 181,263 | 116,297 | 32,120 | |||||||
Invested Capital | 1,860,835 | 1,460,391 | 1,384,771 | |||||||
ROIC | 0.02% | |||||||||
ROCE | 0.26% | |||||||||
EV | ||||||||||
Common stock shares outstanding | 29,935 | 29,526 | 28,936 | |||||||
Price | 329.50 80.05% | 183.00 -34.29% | 278.50 -11.31% | |||||||
Market cap | 9,863,631 82.55% | 5,403,248 -32.95% | 8,058,697 -5.55% | |||||||
EV | 9,379,835 | 5,176,302 | 7,670,284 | |||||||
EBITDA | 30,827 | 46,403 | 13,122 | |||||||
EV/EBITDA | 304.27 | 111.55 | 584.54 | |||||||
Interest | 1,190 | 605 | 276 | |||||||
Interest/NOPBT | 14.28% |